# Pharmacology of Antiviral Drugs

**Authors:** David E. Martin

PMC · DOI: 10.3390/v17040459 · Viruses · 2025-03-24

## Full-text entities

- **Diseases:** infectious diseases (MESH:D003141), HIV infection (MESH:D015658), chronic hepatitis B infection (MESH:D019694), bacterial infections (MESH:D001424), HDV infection (MESH:D007239), viral infections (MESH:D014777), anemia (MESH:D000740), Ebola virus disease (MESH:D019142), myositis (MESH:D009220), cancer (MESH:D009369), mitochondrial toxicity (MESH:D028361), injury to (MESH:D014947)
- **Chemicals:** cabotegravir (MESH:C584914), Cabenuva (MESH:C000712547), AZT (MESH:D015215), Long-Acting Antiviral (-), rilpivirine (MESH:D000068696), efavirenz (MESH:C098320), tenofovir disoproxil fumarate (MESH:D000068698)
- **Species:** Homo sapiens (human, species) [taxon 9606], Respiratory syncytial virus (no rank) [taxon 12814], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12030841/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12030841/full.md

---
Source: https://tomesphere.com/paper/PMC12030841